EKF Diagnostics (LON:EKF) Stock Passes Above 200-Day Moving Average – Should You Sell?

Shares of EKF Diagnostics Holdings plc (LON:EKF) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 25.35 and traded as high as GBX 26.90. EKF Diagnostics shares last traded at GBX 26.50, with a volume of 110,948 shares.

Analyst Ratings Changes

Separately, Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 35 price target on shares of EKF Diagnostics in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of GBX 35.

EKF Diagnostics Stock Performance

The company has a market capitalization of £114.08 million, a PE ratio of 56.38 and a beta of 0.53. The company has a 50 day moving average of GBX 25.24 and a two-hundred day moving average of GBX 25.35. The company has a debt-to-equity ratio of 2.01, a current ratio of 4.16 and a quick ratio of 1.77.

EKF Diagnostics (LON:EKF) last issued its quarterly earnings results on Tuesday, March 24th. The company reported GBX 0.47 earnings per share for the quarter. EKF Diagnostics had a return on equity of 3.01% and a net margin of 4.12%. As a group, equities research analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.